NRx Pharmaceuticals (NRXP) Projected to Post Quarterly Earnings on Friday

NRx Pharmaceuticals (NASDAQ:NRXP) is expected to post its quarterly earnings results before the market opens on Friday, April 4th. Analysts expect NRx Pharmaceuticals to post earnings of ($0.20) per share for the quarter.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.10). On average, analysts expect NRx Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NRx Pharmaceuticals Stock Performance

NASDAQ:NRXP opened at $2.07 on Friday. The stock has a 50-day simple moving average of $2.61 and a two-hundred day simple moving average of $2.04. NRx Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $6.01. The firm has a market capitalization of $35.02 million, a PE ratio of -0.97 and a beta of 1.22.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on NRXP shares. Ascendiant Capital Markets raised their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. D. Boral Capital restated a “buy” rating and set a $31.00 target price on shares of NRx Pharmaceuticals in a research note on Monday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $19.00 target price on shares of NRx Pharmaceuticals in a report on Thursday, March 20th.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.